Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Adaptimmune Therapeutics PLC (ADAP)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15
   10-K10-K10-K10-K10-K10-K10-K8-K
    Total interest income         0.8
Net interest income         0.8
Pre-tax income  -163.0-157.3-129.9-136.9-95.0-69.7-70.7-39.4
Income taxes  2.50.80.20.20.50.50.90.1
Net income  -165.5-158.1-130.1-137.2-95.5-70.1-71.6-39.5
            Net margin  -609.5%-2571.0%-3286.8%-12225.0%-160.5%-185.4%-504.1%-272.7%
   
Basic EPS  ($0.17)($0.17)($0.15)($0.22)($0.16)($0.13)($0.17) 
Diluted EPS  ($0.17)($0.17)($0.15)($0.22)($0.16)($0.13)($0.17) 
   
Shares outstanding (basic)  967.2934.8854.8629.8584.3527.6424.7 
Shares outstanding (diluted)  967.2934.8854.8629.8584.3527.6424.7 
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy